Table 3.
HIV Positive-Derived A02+ HPA-T Epitope Mapping
| Product Name |
HLA Type |
Epitope Mapping |
|||
|---|---|---|---|---|---|
| HPA-T | HLA Class I | HLA Class II | NEF | GAG | POL |
| HPA-T #1 | A02, 03; B07, 40; C03, 07 | DRB1 04, 15; DQB1 03, 06; DRB4 01; DRB5 01; DQA 01, 03 | EEEVGFPVRPQVPLR | RQANFLGKIWPSNKG | PQGWKGSPAIFQSSM |
| GFPVRPQVPLRPMTY | FLGKIWPSNKGRPGN | KGSPAIFQSSMTKIL | |||
| RPQVPLRPMTYKAAL | AIFQSSMTKILEPFR | ||||
| DLSHFLKEKGGLEGL | |||||
| FLKEKGGLEGLIYSK | |||||
| HPA-T #2 | A02, 03; B07, 52; C07, 12 | DRB1 15, 15; DRB5 01, 01; DQA1 01, 01; DQB1 06, 06; DPB1 04, 04 | RPQVPLRPMTYKAAL | VGGPGHKARVLAEAM | KGSPAIFQSSMTKIL |
| TPGPGIRYPLTFGW | SLYNTVATL | AIFQSSMTKILEPFR | |||
| HPA-T #3 | A02, 02; B35, 44; C04, 05 | DRB1 01,04; DRB4 01; DQA1 01, 03; DQB1 05, 03; DPB1 04, 04 | PGIRYPLTFGWCFKL | – | – |
| YPLTFGWCFKLVPV | |||||
| HPA-T #4 | A02, 26; B15, 44; C02, 03 | DRB1 04,11; DRB3 02; DRB4 01; DQA1 03, 05; DQB1 03, 03; DPB1 02, 04 | DLSHFLKEKGGLEGL | ASVLSGGKLDAWEKI | ANRETKLGKAGYVTD |
| FLKEKGGLEGLIYSK | EKIRLRPGGKKKYRL | THLEGKIILVAVHVA | |||
| FSALSEGATPQDLNT | GKIILVAVHVASGYI | ||||
| WIILGLNKIVRMYSP | |||||
| GLNKIVRMYSPVSIL | |||||
| HPA-T #5 | A02, 11; B15, 15; C08, 08 | unknown | RPQVPLRPMTYKAAL | GLNKIVRMYSPVSIL | KKKSVTVLDVGDAYF |
| DRFFKTLRAEQATQ | VTVLDVGDAYFSVPL | ||||
| HPA-T #6 | A02, 32; B15, 40; C02, 03; | DRB1 01, 14; DQB1 05, 05; DRB3 02; DQA 01 | – | LDAWEKIRLRPGGKK | QKQITKIQNFRVYYR |
| EKIRLRPGGKKKYRL | TKIQNFRVYYRDSRD | ||||
| YRLKHLVWASRELER | DDCVASRQDED | ||||
| WIILGLNKIVRMYSP | |||||
| GLNKIVRMYSPVSIL | |||||
| VSILDIRQGPKEPFR | |||||
HPA-Ts were mapped with overlapping 15 mers based on HIV-1 consensus sequences of Gag, Nef, and Pol. HPA-T no. 2 (OM9) is the de-identified HIV+ donor from which SL9-specific T cells are derived from in Figures 4C and 4D. Known HLA-A02 epitopes (based on LAND) are shown in bold with unknown HLA restrictions.